Abstract: The present invention provides crosslinking pairs of hydrogel precursor polymers, dynamic covalent hydrogels prepared from such crosslinking pairs of hydrogel precursors, pharmaceutical compositions comprising such precursors or hydrogels and uses thereof in a variety of applications.

Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

Abstract: The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.

Abstract: The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si—HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.

Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

Abstract: The invention concerns: —a silylated biomolecule having the following formula (I): —the process for the preparation of a silylated biomolecule of formula (I), —the use of a silylated biomolecule of formula (I) to functionalize the surface of a support, —a process for the preparation of a hydrogel by use of a silylated biomolecule of formula (I), the hydrogel obtainable by said process, —said hydrogel as a biological tissue substitute, —a composition comprising said hydrogel in a pharmaceutically acceptable vehicle, —said composition for the release of active principle.

Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

Abstract: The invention provides chondrogenic differentiation media comprising chondrogenic growth factors and low-molecular-weight sulfated polysaccharide derivatives of marine native exopolysaccharides (EPS) excreted by mesophilic marine bacteria from deep-sea hydrothermal environments. The invention relates to methods for inducing chondrogenic differentiation in pluripotent or multipotent cells, to cartilage tissues obtained by such methods, and to the use of such cartilage tissues for therapeutic purposes.

Abstract: The invention relates to the use of a silanised hydroxypropylmethylcellulose (HPMC) or silanised hydroxyethylcellulose (HEC) hydrogel, self-crosslinking as a function of pH, for the three-dimensional ex vivo culture of chondrocytes.

Abstract: The invention concerns: a silylated biomolecule having the following formula (I): the process for the preparation of a silylated biomolecule of formula (I), the use of a silylated biomolecule of formula (I) to functionalize the surface of a support, a process for the preparation of a hydrogel by use of a silylated biomolecule of formula (I), the hydrogel obtainable by said process, said hydrogel as a biological tissue substitute, a composition comprising said hydrogel in a pharmaceutically acceptable vehicle, said composition for the release of active principle.

Abstract: A phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultras-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. The compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium.

Abstract: The invention relates to the use of a silanised hydroxypropylmethylcellulose (HPMC) or silanised hydroxyethylcellulose (HEC) hydrogel, self-crosslinking as a function of pH, for the three-dimensional ex vivo culture of chondrocytes.

Abstract: A phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultras-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. The compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium.

Abstract: The invention concerns a phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultra-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. Said compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium.

Abstract: A composition and method for producing interconnective macroporous, resorbable and injectable calcium phosphate-based cements (MICPCs). The composition of the invention sets to poorly crystalline apatitic calcium phosphate after mixing a powder component and an aqueous solution. The multiphasic calcium phosphate components in the cement resorb at different rates allowing the timely replacement by new bone. The interconnected macroporosity in the cement allows for vascularization, entrapment of growth factors, cell colonization and tissue ingrowth. This MICPC can be used for dental and medical applications relating to bone repair, augmentation, reconstruction, regeneration, and osteoporosis treatment, and also for drug delivery, and as scaffolds for tissue engineering.

Abstract: The invention relates to the use of a silanised hydroxypropylmethylcellulose (HPMC) or silanised hydroxyethylcellulose (HEC) hydrogel, self-crosslinking as a function of pH, for the three-dimensional ex vivo culture of chondrocytes.

Abstract: The invention concerns a phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultra-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. Said compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium.

Abstract: A composition and method for producing interconnective macroporous, resorbable and injectable calcium phosphate-based cements (MICPCs). The composition of the invention sets to poorly crystalline apatitic calcium phosphate after mixing a powder component and an aqueous solution. The multiphasic calcium phosphate components in the cement resorb at different rates allowing the timely replacement by new bone. The interconnected macroporosity in the cement allows for vascularization, entrapment of growth factors, cell colonization and tissue ingrowth. This MICPC can be used for dental and medical applications relating to bone repair, augmentation, reconstruction, regeneration, and osteoporosis treatment, and also for drug delivery, and as scaffolds for tissue engineering.